Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
ZNF865 (BLST), a previously uncharacterized zinc finger protein, has been identified as a regulator of genomic stability and cellular senescence in the intervertebral disc. Its expression declines with age and degeneration in human and mouse discs, and experimental suppression drives senescence, DNA damage, disc degeneration, and pain behavior in rodents, while restoration reverses senescent features and restores chromatin accessibility toward a healthy state. The finding links a discrete molecular control point to both tissue aging and the clinical experience of pain.
Tiny Health raised a $33m Series B to expand shotgun metagenomic microbiome testing from infants to adults, with adult samples now exceeding pediatric volume. Its strongest evidence is a 2025 randomized controlled trial reporting an 83% reduction in the odds of infant eczema following targeted microbiome intervention. The company acknowledges there is no universal definition of a healthy adult microbiome and that its new longevity-oriented scores have not yet been shown to predict health outcomes.
Swedish biotech Alzinova will present the design of its global Phase IIa ADVANCE trial for ALZ-101, a therapeutic vaccine targeting toxic amyloid-beta oligomers, at the Clinical Trials on Alzheimer's Disease conference in November. The randomized, double-blind, placebo-controlled study carries a primary endpoint of therapeutic effect rather than safety alone, with first enrollment expected around the turn of 2026 into 2027. A vaccine approach to amyloid, if validated, would represent a more durable and less resource-intensive alternative to the antibody infusions currently dominating the field.
A conference at the European Parliament on October 1, hosted by MEP Valentina Palmisano and organized by the Longevity Policies Association and International Longevity Alliance, pressed for geroscience and preventive medicine to be treated as a distinct EU health policy field rather than a subset of pension and social care planning. Speakers from the Commission, clinical practice and research argued that biomedical advances in aging biology stall without a framework to carry them into population health. The practical test is whether the effort secures funding in FP10 and regulatory language, not whether it generates further discussion.
A fatty acid produced by the gut bacterium Bacteroides uniformis — pentadecanoic acid (C15:0) — reduced atherosclerotic plaque burden and circulating LDL cholesterol in mice prone to arterial disease. The mechanism runs through the liver: the molecule suppresses hepatic cholesterol synthesis, which activates SREBP2 and upregulates LDL receptors to clear more cholesterol from the blood. Effects were slightly weaker than atorvastatin, and the study measured slowed progression rather than plaque reversal.
Jupiter Neurosciences has dosed the first patient in RESET, a Phase 2a randomized, double-blind, placebo-controlled trial of JOTROL — a micellar trans-resveratrol formulation — in approximately 30 Parkinson's disease patients over 12 weeks. Primary endpoints are safety, tolerability and pharmacokinetics, with exploratory biomarkers covering energy metabolism and inflammation. Phase 1 data reportedly showed increased systemic exposure and measurable cerebrospinal fluid concentrations without serious adverse events.
AgelessRx has released a prescription copper peptide (GHK-Cu) cream in two compounded strengths, 0.5% and 3%, intended to support skin repair processes that decline with age. Each prescription requires review by a licensed provider, and the company reports 99.8% purity alongside microbial and endotoxin testing; compounded formulations are not FDA-approved. The launch places a well-characterized endogenous peptide into a clinician-supervised dosing model rather than an over-the-counter cosmetic one.
In 21,446–29,713 UK Biobank participants, higher birthweight was associated with younger proteomic age across 11 organ systems, with the strongest signals in intestine, esophagus, and stomach. Breastfeeding showed organ-specific associations — slower intestinal and adrenal aging but modestly faster thyroid aging — and combined exposure produced the most favorable multi-organ profiles. Allostatic load mediated up to 35.3% of the birthweight association, indicating that cumulative physiological burden in adulthood carries part of the early-life signal forward.
Measurements of autophagy flux in human tissue show that the cellular recycling process is not uniformly diminished with age but remodeled in patterns that differ by sex and by cell type. Lower flux in older adults corresponded with reduced physical function, linking a core quality-control mechanism to measurable performance decline.
Across two large longitudinal cohorts totaling more than 468,000 adults in Israel and a matched US network, serum 25-hydroxyvitamin D below 10 ng/mL was associated with substantially higher all-cause mortality (adjusted HR 2.57 and 1.59) and elevated risk across metabolic, cardiovascular, renal, neurodegenerative, and microvascular outcomes. Pharmacy-dispensed supplementation modeled longitudinally showed dose-dependent risk reduction, with a mortality hazard ratio of 0.72 for exposure equivalent to raising serum levels by more than 10 ng/mL. Marginal structural Cox models with inverse-probability weighting produced results consistent with conventional adjustment, strengthening the case for a modifiable contribution.
Analysis of published anti-aging intervention studies found that single-clock epigenetic results frequently fail to replicate when additional clock models are applied, with no further clocks reaching statistical significance. The authors propose three criteria for credible results: response in reliable principal-component-based clocks, response in mortality-trained or pace-of-aging clocks, and concordant direction across multiple clocks. For anyone using methylation age as an endpoint, this reframes a single favorable clock reading as insufficient evidence of biological benefit.
Male mice and humans show accelerated immune aging in midlife, marked by earlier thymic involution, contraction of lymph node structure, and a steeper decline in naive CD8+ T cells. The reduced naive repertoire impairs recognition of tumor antigens and weakens responses to checkpoint immunotherapy, identifying middle age as the point at which sex-divergent immune surveillance begins to matter clinically.